NASDAQ: TWSTTwist Bioscience Corp Stock
$84.95+4.16 (+5.15%)
Updated Jun 16, 2026
TWST Price
$84.95
Fair Value Price
$11.14
Market Cap
$5.29B
52 Week Low
$23.30
52 Week High
$86.94
P/E
-64.36x
P/B
11.62x
P/S
7.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$409.48M
Earnings
-$81.28M
Gross Margin
52.1%
Operating Margin
-19.67%
Profit Margin
-19.8%
Debt to Equity
0.49
Operating Cash Flow
-$56M
Beta
2.36
Next Earnings
Aug 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TWST Overview
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TWST's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
TWST
Ranked#29 of 44
Ranked#29 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.25 | A | |
| $128.34 | B | |
| $100.70 | B |
Be the first to know about important TWST news, forecast changes, insider trades & much more!
TWST News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TWST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TWST ($84.95) is overvalued by 662.61% relative to our estimate of its Fair Value price of $11.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TWST ($84.95) is not significantly undervalued (662.61%) relative to our estimate of its Fair Value price of $11.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TWST due diligence checks available for Premium users.
Valuation
TWST fair value
Fair Value of TWST stock based on Discounted Cash Flow (DCF)
Price
$84.95
Fair Value
$11.14
Overvalued by
662.61%
TWST ($84.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TWST ($84.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TWST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-64.36x
Industry
16.18x
Market
13.25x
TWST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.62x
Industry
3.53x
TWST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TWST's financial health
Profit margin
Revenue
$110.7M
Net Income
-$44.0M
Profit Margin
-39.8%
TWST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TWST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$676.2M
Liabilities
$221.1M
Debt to equity
0.49
TWST's short-term assets ($323.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TWST's short-term assets ($323.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TWST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TWST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.6M
Investing
-$12.7M
Financing
$4.1M
TWST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TWST vs Diagnostic & Research Stocks
Twist Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.